IP Library Granted Patent US 9,283,272
Granted Patent B2
US 9,283,272 · App. 13/844,318 · Granted Mar 15, 2016

Targeting intracellular target-binding determinants with intracellular antibodies

Inventors: Richard H. Weisbart (Sepulveda, CA); Robert N. Nishimura (Sepulveda, CA)
Assignee: The United States of America as represented by the Department of Veterans Affairs
A61K39/39558C07K16/30C07K16/44A61K2039/505A61K2039/507C07K2317/31C07K2317/622C07K2317/73C07K2317/77
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,283,272
App. No.
13/844,318
Granted
Mar 15, 2016
Kind
B2
Abstract

The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.

Claims (4)

1. A method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell, and wherein the second Fv fragment is directed to the Mdm2 oncoprotein, thereby inhibiting the intracellular target.

2. The method of claim 1 , wherein the second Fv fragment comprises an anti-Mdm2 oncoprotein mAb 3G5 idiotype or an idiotype that competes with a monoclonal antibody directed to the Mdm2 oncoprotein mAb 3G5.

3. A bispecific antibody comprising a first Fv fragment with a cell-penetrating determinant from an anti-DNA monoclonal antibody 3E10 or an antibody which competes with monoclonal antibody 3E10 and a second Fv fragment with an intracellular target-binding determinant that inhibits the biological activity, biochemical activity, regulatory activity or cellular signal associated with the determinant or a macromolecule to which the determinant is attached, wherein the second Fv fragment is directed to the Mdm2 oncoprotein.

4. The bispecific antibody of claim 3 , wherein the second Fv fragment comprises an anti-Mdm2 oncoprotein mAb 3G5 idiotype or an idiotype that competes with a monoclonal antibody directed to the Mdm2 oncoprotein mAb 3G5.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2014
From: WEISBART, RICHARD H.; NISHIMURA, ROBERT N.
To: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 033401/0239 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2013
From: WEISBART, RICHARD H.; NISHIMURA, ROBERT N.
To: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 030649/0646 →
Continuity (2)
Provisional Application 61618613 · Mar 30, 2012
Related Publication 20130266570A1 · Oct 10, 2013